Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

BACKGROUND/AIMS: The immune-tolerant (IT) phase of chronic hepatitis B (CHB) patients is not generally indicative of antiviral therapy (AVT). We assessed and compared the risk of hepatocellular carcinoma (HCC) during the IT-phase stringently defined by a low fibrosis-4 (FIB-4) index, compared to tha...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Mol Hepatol
Hlavní autoři: Jeon, Mi Young, Kim, Beom Kyung, Lee, Jae Seung, Lee, Hye Won, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Han, Kwang-Hyub, Kim, Seung Up
Médium: Artigo
Jazyk:Inglês
Vydáno: The Korean Association for the Study of the Liver 2021
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8046628/
https://ncbi.nlm.nih.gov/pubmed/33317247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2020.0216
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky